Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study

被引:535
|
作者
Garnero, P
Sornay-Rendu, E
Claustrat, B
Delmas, PD
机构
[1] Hop Edouard Herriot, INSERM, Res Unit 403, F-69437 Lyon 03, France
[2] Hop Neurocardiol, Ctr Med Nucl, Lyon, France
关键词
osteoporosis; bone markers; estrogens; androgens; parathyroid hormone;
D O I
10.1359/jbmr.2000.15.8.1526
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The mechanisms leading to increased bone loss and skeletal fragility in women with postmenopausal osteoporosis are still poorly understood. Increased bone resorption, low serum estradiol and high serum sex-hormone-binding globulin (SHBG) recently have been reported as predictors of vertebral and hip fractures in elderly women. In a cohort of healthy untreated younger postmenopausal women aged 50-89 years (mean, 64 years), we compared baseline levels of bone markers and endogenous hormones in 55 women who subsequently had a fracture (20 vertebral and 35 peripheral fractures) with levels in the 380 women who did not fracture during a mean 5 years of follow-up. Women with levels in the highest quartile of four bone resorption markers including urinary-free deoxypyridinoline (D-Pyr), urinary type I collagen N-telopeptides (NTX), and urinary and serum type I collagen C-telopeptides (CTX) had about a a-fold increased risk of fractures compared with women with levels in the three lowest quartiles with relative risk (RR) and 95% CI of 1.8 (1.0-3.4) for free D-Pyr, 1.7 (0.9-3.2) for urinary NTX, 2.3 (1.3-4.1) for urinary CTX, and 2.1 (1.2-3.8) for serum CTX. Serum levels of bone alkaline phosphatase (BAP) in the highest quartile were associated with an RR of fracture of 2.4 (1.3-4.2). Women with serum levels of estradiol and dehydroepiandrosterone (DHEA) sulfate in the lowest quartile had an RR of fracture of 2.2 (1.2-4.0) and 2.1 (1.2-3.8), respectively. Increased levels of SHBG and intact parathyroid hormone (PTH) were moderately associated with an increased risk of fracture. Similar results were obtained when the analysis was restricted to symptomatic vertebral and nonvertebral fractures. Adjustment of biochemical markers by hormone levels did not significantly alter the results. Women with both high bone resorption markers and low estradiol (or low DHEA sulfate) had a higher risk of fracture with RRs of 3.0-3.3 (p < 0.001). After adjustment for bone mineral density (BMD) of the hip, spine, radius, or total body, bone markers and hormones were still predictive of fracture risk with similar RRs. We conclude that high levels of some biochemical markers of bone turnover, low serum estradiol, low DHEA sulfate, high SHBG, and high PTH are associated with increased risk of osteoporotic fracture in postmenopausal women, independently of each other and of BMD. The mechanism by which some postmenopausal women have an increased rate of bone turnover leading to an increased risk of fracture remains to be elucidated.
引用
收藏
页码:1526 / 1536
页数:11
相关论文
共 50 条
  • [21] Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women
    Komi, J
    Heikkinen, J
    Rutanen, EM
    Halonen, K
    Lammintausta, R
    Yikorkala, O
    GYNECOLOGICAL ENDOCRINOLOGY, 2004, 18 (03) : 152 - 158
  • [22] Effect of statins on bone turnover markers in postmenopausal women: a pilot study
    Walczak, Marta
    Braszak-Cymerman, Anna
    Bielawska, Lena
    Bryl, Wieslaw
    POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2023, 19 (04): : 367 - 370
  • [23] Bone turnover markers and estradiol level in postmenopausal women
    Sypniewska, G
    Chodakowska-Akolinska, G
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2000, 38 (11) : 1115 - 1119
  • [24] Bone Turnover Markers and Vitamin D Status in Postmenopausal Turkish Women
    Genc, Sema
    Omer, Beyhan
    Aycan-Ustyol, Esra
    Kumral, Alkin
    Gurdol, Figen
    INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH, 2012, 82 (01) : 27 - 33
  • [25] Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women
    Shiraki, M.
    Sugimoto, T.
    Nakamura, T.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 219 - 226
  • [26] Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia
    Naylor, K. E.
    Jacques, R. M.
    Peel, N. F. A.
    Gossiel, F.
    Eastell, R.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 (08) : 2585 - 2592
  • [27] Short-term risedronate treatment in postmenopausal women: Effects on biochemical markers of bone turnover
    Raisz, L
    Smith, JA
    Trahiotis, M
    Fall, P
    Shoukri, K
    DiGennaro, J
    Sacco-Gibson, N
    OSTEOPOROSIS INTERNATIONAL, 2000, 11 (07) : 615 - 620
  • [28] Association of Endogenous Hormones and Bone Mineral Density in Postmenopausal Women
    Garcia-Alfaro, Pascual
    Garcia, Sandra
    Rodriguez, Ignacio
    Pascual, Maria Angela
    Perez-Lopez, Faustino R.
    JOURNAL OF MID-LIFE HEALTH, 2023, 14 (03) : 196 - 204
  • [29] Age-related changes in bone turnover markers and ovarian hormones in premenopausal and postmenopausal Indian women
    Desai, Meena P.
    Bhanuprakash, K. V.
    Khatkhatay, M. Kram
    Donde, Uday M.
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2007, 21 (02) : 55 - 60
  • [30] Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study
    Gineyts, E.
    Munoz, F.
    Bertholon, C.
    Sornay-Rendu, E.
    Chapurlat, R.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (02) : 243 - 250